PathAI short form for Pathology Artificial Intelligence, is one of the pioneer companies using AI in pathology diagnostics. It was founded in 2016 by Dr. Andrew Beck and Aditya Khosla, and is headquartered in Boston, Massachusetts, USA.
With a mission to enhance the accuracy and efficiency of disease diagnosis, PathAI develops AI-powered solutions that assist pathologists in detecting and analyzing various diseases, including cancer.
By leveraging advanced machine learning algorithms, PathAI aims to improve patient outcomes, reduce diagnostic errors, and pave the way for more personalized treatment strategies in the ever-evolving landscape of healthcare.
Path AI has steadily grown its team since its inception, attracting top talent in the fields of pathology, artificial intelligence, and healthcare technology. PathAI specializes in precision pathology solutions that integrate deep computational expertise with medical insights.
Leveraging data from a rich repository of over 15 million annotations contributed by their proprietary pathology network of 450+ pathologists, along with an extensive archive of medical data, they rigorously train and validate their AI-based models, enhancing diagnostic accuracy, and expediting the delivery of life-saving therapies.
Path AI has achieved significant milestones, solidifying its position as a leader in precision pathology solutions. In 2019, the company received certifications for quality management and information security standards, published groundbreaking research, and secured its first patents.
In 2020, Path AI made its mark in academia with its inaugural manuscript published in Hepatology.
The following year, 2021, saw PathAI secure substantial funding and expand into clinical diagnostics through strategic acquisitions.
In 2022, PathAI further enhanced its capabilities by establishing an in-house CAP/CLIA-certified histopathology lab, reinforcing its ability to support end-to-end clinical trials for its BioPharma partners. The company received FDA clearance and CE Mark for its digital pathology platform, AISight Dx, paving the way for its use in primary diagnosis in clinical settings.
With total funding of $255.49M till this date, PathAI is continuing to progress commercially and in research and development capabilities.